Vigabatrin
- Atc Codes:N03AG04
- CAS Codes:60643-86-9
- PHARMGKB ID:60643-86-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Sabril; Belgium: Sabril; Czech Republic: Sabril; Denmark: Sabrilex; Finland: Sabrilex; France: Sabril; Germany: Sabril; Greece: Sabril; Hungary: Sabril; Ireland: Sabril; Italy: Sabril; Latvia: Sabril; Luxembourg: Sabril; Netherlands: Sabril; Poland: Sabril; Portugal: Sabril; Slovakia: Sabril; Spain: Sabrilex; Sweden: Sabrilex; UK: Sabril.
North America
Canada: Sabril.
Latin America
Argentina: Sabril; Brazil: Sabril; Mexico: Sabril.
Asia
Japan: Vigabatrin.
Drug combinations
Chemistry
Vigabatrin: C~6~H~11~NO~2~. Mw: 129.16. 5-Hexenoic acid, 4-amino-. CAS-60643-86-9 (1985).
Pharmacologic Category
Anticonvulsants, Miscellaneous. (ATC-Code: N03AG04).
Mechanism of action
Irreversibly inhibits gamma-aminobutyric acid transaminase (GABA-T), increasing levels of inhibitory compound GABA within brain. Duration of effect dependent upon rate of GABA-T resynthesis.
Therapeutic use
Active management of partial or secondary generalized seizures. Treatment of infantile spasms.
Pregnancy and lactiation implications
Animal studies indicate fetal malformation and neurotoxicity. Not recommended during pregnancy or breast-feeding.
Unlabeled use
Spasticity, tardive dyskinesias.
Contraindications
Hypersensitivity to vigabatrin or any component of the formulation. Pregnancy or breast-feeding.
Warnings and precautions
Potential neurotoxicity (observed in animal models but not established in humans). Visual disturbances may be associated with ophthalmologic toxicities, may be permanent. Use with caution in history of psychosis (psychotic/agitated reactions may occur more frequently), depression, or behavioral problems. Use with caution in renal impairment (CrCl <60 mL/minute). May cause increase in seizure frequency in some patients (use with particular caution in myoclonic seizures). Effects with other sedative drugs or ethanol may be potentiated. Use with caution in the elderly. Anticonvulsants should not be discontinued abruptly.